Genotype-phenotype investigation of evolving mutations associated with antimalarial resistance among Senegalese Plasmodium falciparum malaria parasites

Drug resistance in Plasmodium falciparum threatens malaria control and elimination efforts, particularly where sustained chemoprevention and treatment have driven parasite evolution. Senegal has implemented antimalarial strategies for two decades, including sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment in pregnancy and SP plus amodiaquine for seasonal malaria chemoprevention in children. We analyzed whole-genome sequencing (WGS) data from 2,805 monogenomic P. falciparum infections collected from febrile, treatment-seeking patients across Senegal between 2006 and 2022. Wild-type (WT), drug-sensitive alleles at four major resistance loci ( Pfcrt , Pfmdr1 , Pfdhfr , and Pfdhps ) were rare, while resistance-associated variants, including Pfcrt K76T, the canonical Pfdhfr triple mutant (N51I, C59R, S108N), and Pfdhps A437G, predominated. To define how these genotypes shape drug response and parasite fitness, we cultured 33 clinical isolates representing 26 common combined haplotypes, which together accounted for 63.9% of infections in the WGS dataset. Multivariable mixed-effects models revealed drug- and background-dependent effects. Relative to the Pfcrt WT, the CVIET background increased monodesethyl-amodiaquine EC 50 approximately 1.4-fold; adding N326S or I356T produced cumulative increases of approximately 2.6-fold and 3.2-fold, respectively. The Pfdhfr triple mutant increased pyrimethamine EC 50 approximately 2,196-fold relative to Pfdhfr WT. For sulfadoxine, Pfdhps A437G was associated with an approximately 463,000-fold increase in EC 50 relative to WT, while Pfdhps S436A had little effect. Pairwise competitive growth outcomes analyzed with a Bradley-Terry model showed reduced competitive ability for Pfcrt CVIET , partially rescued by Pfmdr1 Y184F; Pfdhps S436A increased whereas A613S reduced competitive ability. These findings reveal resistance-fitness trade-offs that may shape P. falciparum evolution as antimalarial policies change across Africa.

Authors

Institutions

Publication Details

Journal
PLoS Pathogens
Published
2026-11-19
DOI
https://doi.org/10.1371/journal.ppat.1014822
Citations
3
Primary Topic
Malaria Research and Control
Type
article
Field-Weighted Citation Impact
10.80
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Genotype-phenotype investigation of evolving mutations associated with antimalarial resistance among Senegalese Plasmodium falciparum malaria parasites

Khadim Diongue, Dyann F. Wirth, Awa Bineta DEME, Aita Sène et al.
3 citations
PLoS Pathogens
Malaria Research and Control
10.80
article

Genotype-phenotype investigation of evolving mutations associated with antimalarial resistance among Senegalese Plasmodium falciparum malaria parasites

Khadim Diongue, Dyann F. Wirth, Awa Bineta DEME, Aita Sène, Nogaye Gadiaga, Mariama Touré, Imran Ullah, Jules François Gomis, Bronwyn L. MacInnis, Stephen F. Schaffner, Mamadou Samb YADE, Katelyn M. Vendrely, Djiby Sow, Sarah K. Volkman, Younouss Diédhiou, Wesley Wong, Amy Gaye, Mamadou Alpha Diallo, Mame Fatou NDIAYE, Baba Dièye, Mouhamadou Ndiaye, Daouda Ndiaye, Karina Bellavia
article en
3 citations

Abstract

Drug resistance in Plasmodium falciparum threatens malaria control and elimination efforts, particularly where sustained chemoprevention and treatment have driven parasite evolution. Senegal has implemented antimalarial strategies for two decades, including sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment in pregnancy and SP plus amodiaquine for seasonal malaria chemoprevention in children. We analyzed whole-genome sequencing (WGS) data from 2,805 monogenomic P. falciparum infections collected from febrile, treatment-seeking patients across Senegal between 2006 and 2022. Wild-type (WT), drug-sensitive alleles at four major resistance loci ( Pfcrt , Pfmdr1 , Pfdhfr , and Pfdhps ) were rare, while resistance-associated variants, including Pfcrt K76T, the canonical Pfdhfr triple mutant (N51I, C59R, S108N), and Pfdhps A437G, predominated. To define how these genotypes shape drug response and parasite fitness, we cultured 33 clinical isolates representing 26 common combined haplotypes, which together accounted for 63.9% of infections in the WGS dataset. Multivariable mixed-effects models revealed drug- and background-dependent effects. Relative to the Pfcrt WT, the CVIET background increased monodesethyl-amodiaquine EC 50 approximately 1.4-fold; adding N326S or I356T produced cumulative increases of approximately 2.6-fold and 3.2-fold, respectively. The Pfdhfr triple mutant increased pyrimethamine EC 50 approximately 2,196-fold relative to Pfdhfr WT. For sulfadoxine, Pfdhps A437G was associated with an approximately 463,000-fold increase in EC 50 relative to WT, while Pfdhps S436A had little effect. Pairwise competitive growth outcomes analyzed with a Bradley-Terry model showed reduced competitive ability for Pfcrt CVIET , partially rescued by Pfmdr1 Y184F; Pfdhps S436A increased whereas A613S reduced competitive ability. These findings reveal resistance-fitness trade-offs that may shape P. falciparum evolution as antimalarial policies change across Africa.

PLoS PathogensVol. 22(11)
Broad Institute (US), Harvard University (US), Simmons University (US), Cheikh Anta Diop University (SN)
Good health and well-being
Openalex Percentile: Top 3%
Malaria Research and Control
10.80
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon